Navigation Links
The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008
Date:8/18/2008

Quarterly Reports use Market Intelligence and Competitive Analysis from Thomson Reuters to Explore Various Aspects of the Pharmaceutical Pipeline

LONDON and PHILADELPHIA, Aug. 18 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has announced the availability of the Pharma Matters reports covering the time period January-March 2008. Launched more than two years ago, the quarterly Pharma Matters reports cover all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping System(SM).

The Ones to Watch -- A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on the strategic data and analysis from Thomson Pharma, the world's leading pharmaceutical competitive intelligence solution. In the report covering Q1 2008, the top five most promising drugs launched or receiving approval were:

DRUG DISEASE COMPANY

Intelence(TM) HIV-1 infection Tibotec

Pristiq(TM) Depression Wyeth

Ionsys(TM) Acute pain ALZA

Arcalyst(TM) CIAS1-associated Regeneron

periodic syndromes

Moxatag(TM) Streptococcus MiddleBrook

pyogenes-associated

pharyngitis, tonsillitis

More analysis, as well as information on drugs entering clinical Phases I, II and III, are available in the full report: http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/totw_jan -march_08.pdf

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

Movers and Shakers -- Introduced in mid-2007, this report is the newest in the Pharma Matters series and covers the U.S. generics industry using data and analysis from Newport Horizon Premium, the critical product targeting the global business development system. Analysis from the Q1 2008 report includes:
-- The U.S. generics market is remarkably robust but will be hit by the

current downturn in drugs innovation, which will translate into a

decline in off-patent drugs from 2012.

-- 'Super Generic' companies such as Teva and Mylan now dominate the

generics market and will be the best placed to survive any future

downturns.

-- During the first quarter of 2008, final approvals were issued on 134

'A'-rated ANDAs, up from 108 the quarter before.

-- 11 new products (four combination products and seven single active

ingredient products) were subjected to paragraph IV challenges for the

first time in Q1 2008, in comparison to the challenges made to seven

new products in the last quarter of 2007.

-- During the first quarter of 2008, the largest number of ANDA approvals

went to US-based companies. Thirty different US-based corporations

received a total of 59 final ANDA approvals.

-- In the same time period, fourteen India-based companies received a

total of 36 approvals, putting India in second place.

To learn more about companies making their mark on the U.S. generics market, click on this link to read the full report: http://scientific.thomson.com/thomsonpharma/media/pdfs/tpqr/movers_shakers_ jan-mar08.pdf

(Due to the length, copy and paste URL into browser window.)

Who is Making the Biggest Splash? -- This report is a Thomson Reuters expert review of the organizations that are helping to shape professional opinions on drugs and therapies, using the unique insights of the Thomson Message Mapping System. In this quarterly review of the scientific literature on drugs and therapies, Thomson Reuters assesses the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The top five of the listed 15 organizations that have made the biggest impact as the leading sources of information on medical research from January-March 2008 are:

1. Eli Lilly

2. sanofi-aventis

3. Novartis

4. Bristol-Myers Squibb

5. GlaxoSmithKline

To see the complete list, as well as analysis and methodology, click to read the full report: http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/making-a -splash-mar2008.pdf

(Due to the length, copy and paste URL into browser window.)

To sign up for the Thomson Reuters Pharma Matters series of publications visit: scientific.thomson.com/pharma/forms/matters/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. Thomson Scientific Predicts Nobel Laureates
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. Thomson Scientific Announces BONDplus for Biological Researchers
5. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
6. International Society of Hair Restoration Surgery Hosts 15th Annual Scientific Meeting in Las Vegas, September 26-30, 2007
7. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
8. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
9. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
10. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
11. Delta Dental Plans Association Forms National Scientific Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
(Date:9/13/2017)... has been named the official orthopedic and sports medicine ... 2018 College Football Playoff (CFP) National Championship to be played ... Atlanta, Georgia . OrthoAtlanta is proud to be ... many activities leading up to, and including the national championship ... OrthoAtlanta serves ...
Breaking Medicine Technology: